OBJECTIVE: To investigate whether and how mutations at position 89 of HIV-1 protease were associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype. METHODS: In a database containing pol nucleotide sequences and treatment history, the correlation between PI experience and mutations at codon 89 was determined separately for subtype B and several non-B subtypes. A Bayesian network model was used to map the resistance pathways in which M89I/V is involved for subtype G. The phenotypic effect of M89I/V for several PIs was also measured. RESULTS: The analysis showed that for the subtypes C, F and G in which the wild-type codon at 89 was M compared to L for subtype B, M89I/V was significantly more frequently observed in PI-treated patients displaying major resistance mutations to PIs than in drug-naive patients. M89I/V was strongly associated with PI resistance mutations at codons 71, 74 and 90. Phenotypically, M89I/V alone did not confer a reduced susceptibility to PIs. However, when combined with L90M, a significantly reduced susceptibility to nelfinavir was observed (P < 0.05) in comparison with strains with L90M alone. CONCLUSIONS: The results of the present study show that M89I/V is associated with PI experience in subtypes C, F and G but not in subtype B. M89I/V should be considered a secondary PI mutation with an important effect on nelfinavir susceptibility in the presence of L90M.
OBJECTIVE: To investigate whether and how mutations at position 89 of HIV-1 protease were associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype. METHODS: In a database containing pol nucleotide sequences and treatment history, the correlation between PI experience and mutations at codon 89 was determined separately for subtype B and several non-B subtypes. A Bayesian network model was used to map the resistance pathways in which M89I/V is involved for subtype G. The phenotypic effect of M89I/V for several PIs was also measured. RESULTS: The analysis showed that for the subtypes C, F and G in which the wild-type codon at 89 was M compared to L for subtype B, M89I/V was significantly more frequently observed in PI-treated patients displaying major resistance mutations to PIs than in drug-naive patients. M89I/V was strongly associated with PI resistance mutations at codons 71, 74 and 90. Phenotypically, M89I/V alone did not confer a reduced susceptibility to PIs. However, when combined with L90M, a significantly reduced susceptibility to nelfinavir was observed (P < 0.05) in comparison with strains with L90M alone. CONCLUSIONS: The results of the present study show that M89I/V is associated with PI experience in subtypes C, F and G but not in subtype B. M89I/V should be considered a secondary PI mutation with an important effect on nelfinavir susceptibility in the presence of L90M.
Authors: Joke Snoeck; Rami Kantor; Robert W Shafer; Kristel Van Laethem; Koen Deforche; Ana Patricia Carvalho; Brian Wynhoven; Marcelo A Soares; Patricia Cane; John Clarke; Candice Pillay; Sunee Sirivichayakul; Koya Ariyoshi; Africa Holguin; Hagit Rudich; Rosangela Rodrigues; Maria Belen Bouzas; Françoise Brun-Vézinet; Caroline Reid; Pedro Cahn; Luis Fernando Brigido; Zehava Grossman; Vincent Soriano; Wataru Sugiura; Praphan Phanuphak; Lynn Morris; Jonathan Weber; Deenan Pillay; Amilcar Tanuri; Richard P Harrigan; Ricardo Camacho; Jonathan M Schapiro; David Katzenstein; Anne-Mieke Vandamme Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Roxana M Coman; Arthur Robbins; Maureen M Goodenow; Robert McKenna; Ben M Dunn Journal: Acta Crystallogr Sect F Struct Biol Cryst Commun Date: 2007-03-30
Authors: A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri Journal: Antimicrob Agents Chemother Date: 2008-10-06 Impact factor: 5.191
Authors: Ana T Dumans; Cláudia C Barreto; André F Santos; Mônica Arruda; Thatiana M Sousa; Elizabeth S Machado; Ester C Sabino; Rodrigo M Brindeiro; Amílcar Tanuri; Alberto J Duarte; Marcelo A Soares Journal: Infect Genet Evol Date: 2008-10-17 Impact factor: 3.342
Authors: Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak Journal: Virology Date: 2012-10-13 Impact factor: 3.616